143 related articles for article (PubMed ID: 34856908)
21. Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Carr A; Grund B; Neuhaus J; Schwartz A; Bernardino JI; White D; Badel-Faesen S; Avihingsanon A; Ensrud K; Hoy J;
HIV Med; 2015 Apr; 16 Suppl 1(0 1):137-46. PubMed ID: 25711332
[TBL] [Abstract][Full Text] [Related]
22. Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients.
Casado JL; Santiuste C; Vazquez M; Bañón S; Rosillo M; Gomez A; Perez-Elías MJ; Caballero C; Rey JM; Moreno S
AIDS; 2016 Jun; 30(9):1423-31. PubMed ID: 26919733
[TBL] [Abstract][Full Text] [Related]
23. The benefits of tenofovir discontinuation with or without bisphosphonate therapy in osteoporotic people living with HIV.
Lei JJH; Pereira B; Moyle G; Boffito M; Milinkovic A
HIV Med; 2021 Oct; 22(9):816-823. PubMed ID: 34258828
[TBL] [Abstract][Full Text] [Related]
24. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study.
Bonjoch A; Figueras M; Estany C; Perez-Alvarez N; Rosales J; del Rio L; di Gregorio S; Puig J; Gómez G; Clotet B; Negredo E;
AIDS; 2010 Nov; 24(18):2827-33. PubMed ID: 21045635
[TBL] [Abstract][Full Text] [Related]
25. Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.
Stranix-Chibanda L; Tierney C; Sebikari D; Aizire J; Dadabhai S; Zanga A; Mukwasi-Kahari C; Vhembo T; Violari A; Theron G; Moodley D; George K; Fan B; Sommer MJ; Browning R; Mofenson LM; Shepherd J; Nelson B; Fowler MG; Siberry GK;
PLoS One; 2021; 16(2):e0246272. PubMed ID: 33544759
[TBL] [Abstract][Full Text] [Related]
26. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.
Bernardino JI; Mocroft A; Mallon PW; Wallet C; Gerstoft J; Russell C; Reiss P; Katlama C; De Wit S; Richert L; Babiker A; Buño A; Castagna A; Girard PM; Chene G; Raffi F; Arribas JR;
Lancet HIV; 2015 Nov; 2(11):e464-73. PubMed ID: 26520926
[TBL] [Abstract][Full Text] [Related]
27. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
Glidden DV; Mulligan K; McMahan V; Anderson PL; Guanira J; Chariyalertsak S; Buchbinder SP; Bekker LG; Schechter M; Grinsztejn B; Grant RM
J Acquir Immune Defic Syndr; 2017 Oct; 76(2):177-182. PubMed ID: 28639995
[TBL] [Abstract][Full Text] [Related]
28. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
Cotter AG; Vrouenraets SM; Brady JJ; Wit FW; Fux CA; Furrer H; Brinkman K; Sabin CA; Reiss P; Mallon PW;
J Clin Endocrinol Metab; 2013 Apr; 98(4):1659-66. PubMed ID: 23436922
[TBL] [Abstract][Full Text] [Related]
29. A 10-year follow-up of bone mineral density in HIV-infected youths receiving tenofovir disoproxil fumarate.
Giacomet V; Maruca K; Ambrosi A; Zuccotti GV; Mora S
Int J Antimicrob Agents; 2017 Sep; 50(3):365-370. PubMed ID: 28689877
[TBL] [Abstract][Full Text] [Related]
30. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
McComsey GA; Lupo S; Parks D; Poggio MC; De Wet J; Kahl LP; Angelis K; Wynne B; Vandermeulen K; Gartland M; Cupo M; Aboud M;
AIDS; 2018 Feb; 32(4):477-485. PubMed ID: 29239893
[TBL] [Abstract][Full Text] [Related]
31. Reduced bone mineral density among HIV-infected patients in Taiwan: prevalence and associated factors.
Tsai MS; Hung CC; Liu WC; Chen KL; Chen MY; Hsieh SM; Sheng WH; Sun HY; Shih TT
J Microbiol Immunol Infect; 2014 Apr; 47(2):109-15. PubMed ID: 23073318
[TBL] [Abstract][Full Text] [Related]
32. Impact of tenofovir disoproxil fumarate on bone metabolism and bone mass among perinatally HIV-infected Asian adolescents.
Sudjaritruk T; Bunupuradah T; Aurpibul L; Kosalaraksa P; Kurniati N; Sophonphan J; Ananworanich J; Puthanakit T;
Antivir Ther; 2017; 22(6):471-479. PubMed ID: 27786155
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients.
Aydın OA; Karaosmanoglu HK; Karahasanoglu R; Tahmaz M; Nazlıcan O
Braz J Infect Dis; 2013; 17(6):707-11. PubMed ID: 24076108
[TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis.
Hemkens LG; Ewald H; Santini-Oliveira M; Bühler JE; Vuichard D; Schandelmaier S; Stöckle M; Briel M; Bucher HC
HIV Clin Trials; 2015 Oct; 16(5):178-89. PubMed ID: 26395328
[TBL] [Abstract][Full Text] [Related]
35. Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study.
Mwasakifwa GE; Amin J; White CP; Center JR; Kelleher A; Boyd MA
HIV Med; 2020 Sep; 21(8):492-504. PubMed ID: 32573910
[TBL] [Abstract][Full Text] [Related]
36. BEING: Bone Health in Aging Women with HIV: Impact of Switching Antiretroviral Therapy on Bone Mineral Density During the Perimenopausal Period.
Walmsley S; Clarke R; Lee T; Singer J; Cheung AM; Smaill F; De Pokomandy A; Trottier S; Messina E; Guaraldi G
AIDS Res Hum Retroviruses; 2023 Apr; 39(4):204-210. PubMed ID: 36511389
[TBL] [Abstract][Full Text] [Related]
37. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
[TBL] [Abstract][Full Text] [Related]
38. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy.
Bolland MJ; Horne AM; Briggs SE; Thomas MG; Reid IR; Gamble GD; Grey A
Calcif Tissue Int; 2019 Oct; 105(4):423-429. PubMed ID: 31250043
[TBL] [Abstract][Full Text] [Related]
40. Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.
Boontanondha P; Nimitphong H; Musikarat S; Ragkho A; Kiertiburanakul S
Curr HIV Res; 2020; 18(1):52-62. PubMed ID: 31906840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
